Analysis of cardiovascular safety of novel glucose-lowering medications | Zendy

А. M. Mkrtumyan | Zendy; Т. Н. Маркова | Zendy; Н. К. Мищенко | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Analysis of cardiovascular safety of novel glucose-lowering medications

Author(s) -

А. M. Mkrtumyan,

Т. Н. Маркова,

Н. К. Мищенко

Publication year - 2019

Publication title -

kardiologiia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.159

H-Index - 16

eISSN - 2412-5660

pISSN - 0022-9040

DOI - 10.18087/cardio.2019.7.10267

Subject(s) - empagliflozin , canagliflozin , liraglutide , medicine , pharmacology , dipeptidyl peptidase 4 , glucagon like peptide 1 , type 2 diabetes , diabetes mellitus , clinical trial , glucagon like peptide 1 receptor , endocrinology , receptor , agonist

In 2008 the Food and Drug Administration has revised approval process for new antidiabetic agents and introduced a requirement to demonstrate the cardiovascular safety in an international multicenter trial. Currently cardiovascular outcome trials of dipeptidyl peptidase-4 (DPP-4) inhibitors (SAVOR-TIMI53, EXAMINE and TECOS), sodium-glucose cotransporter 2 inhibitors (EMPAREG, CANVAS), glucagon-like peptide-1 receptor agonists (ELIXA, EXSCEL LEADER and SUSTAIN-6), ultralong-acting and insulin (DEVOTE) have been completed. The trials confirmed cardiovascular safety of these glucose-lowering medications, and in addition, EMPA-REG OUTCOME (empagliflozin), CANVAS (canagliflozin) and LEADER (liraglutide) have also demonstrated cardioprotective effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. These data led to the changes of clinical guidelines for the management of type 2 diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research